Regeneron Pharmaceuticals (NASDAQ:REGN) Hits New 52-Week Low - Here's What Happened

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) reached a new 52-week low during trading on Thursday . The company traded as low as $712.30 and last traded at $714.62, with a volume of 907724 shares traded. The stock had previously closed at $740.01.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on REGN. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday, November 4th. Cantor Fitzgerald reiterated a "neutral" rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a research note on Tuesday. They issued a "hold" rating and a $165.00 price objective for the company. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. Finally, Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $1,052.90.

Regeneron Pharmaceuticals Trading Down 0.9 %

The stock has a market capitalization of $77.83 billion, a PE ratio of 17.53, a P/E/G ratio of 2.19 and a beta of 0.08. The company's 50 day moving average price is $827.27 and its two-hundred day moving average price is $996.84. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Rakuten Securities Inc. grew its holdings in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter worth about $26,000. Sachetta LLC boosted its holdings in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 10 shares during the last quarter. FSA Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Finally, Family Firm Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $33,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.